Molina raises full year 2026 guidance after Q2 results
Molina Healthcare reported Q2 2026 adjusted EPS of $1.51, above the $1.39 consensus. Revenue fell to $10.874B from $11.427B a year earlier, while GAAP net income declined to $60M. The company raised full-year 2026 adjusted guidance to at least $5.25 per diluted share and GAAP to at least $2.15. Analysts at RBC, Wells Fargo, and TD Cowen raised price targets for MOH.
How this was made
The 30-second read
Why it matters
Traders can update valuation and positioning around the new FY adjusted EPS floor ($5.25+) and the implied cost-trend offsets across Medicare and Marketplace.
Market read
Fresh FY guidance and Q2 beat are likely to drive near-term earnings estimate revisions and sentiment for MOH.
What to watch
MCR increased to 92.2% and GAAP net income fell, suggesting underlying cost pressure remains a key swing factor for future quarters.
Background
Molina reported Q2 2026 results and updated full-year 2026 GAAP and adjusted EPS guidance, citing Medicaid performance and developing medical cost trends.
Ticker impact
Molina Healthcare beat Q2 EPS ($1.51 vs $1.39) and raised full-year 2026 adjusted EPS guidance to at least $5.25.
Likely positive bias for MOH as raised FY adjusted EPS provides a fresh earnings anchor, though GAAP income decline and higher MCR may temper upside.
The article provides specific, time-relevant guidance changes (GAAP and adjusted) plus Q2 beat and operating metrics (MCR up to 92.2%), which together define the new fundamental setup for traders.
Market effects
Revised Medicaid/Medicare cost-trend expectations can influence read-across for managed care peers’ earnings models and MCR assumptions.
Primarily US managed care sentiment; limited direct regional spillover beyond healthcare equities.
Low global relevance; mostly impacts US healthcare payer valuation and risk appetite.
Counterpoint
The guidance raise may be partially offset by unfavorable Marketplace and Medicare dynamics, so the market could focus on margin risk rather than the headline EPS.
Key entities
- companyMolina Healthcare
NYSE-listed managed care provider reporting Q2 2026 results and raising FY 2026 GAAP and adjusted EPS guidance.
- analyst_firmRBC Capital
Raised price target to $248 from $216 while maintaining Sector Perform.
- analyst_firmWells Fargo
Raised price target to $235 from $159 while maintaining Equal-Weight.
- analyst_firmTD Cowen
Raised price target to $230 from $163 while maintaining Hold.
